stockrow
Friday 6 November 2026
Export AXGN’s income statement to Excel — free account
AxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.
- Revenue
- +26.2%
- EPS
- +163.2%
- Free cash flow
- +995.0%
- Total debt
- −73.1%
Quarter to September 2026, against a year earlier
49.57
0.82
+1.68%
Follow AXGN
Alert me
AxoGen, Inc. (AXGN) EBITDA
AxoGen, Inc.'s EBITDA for fiscal 2025 was $1.6M, down 71.5% from $5.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$4.1M. Over the past ten years it has ranged from −$28.5M (fiscal 2019) to $5.4M (fiscal 2024); the current reading is higher than 91% of that period. AxoGen, Inc. ranks 52nd of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.6M | (71.52%) |
| FY2024 | $5.4M | — |
| FY2023 | −$15.0M | — |
| FY2022 | −$24.0M | — |
| FY2021 | −$19.8M | — |
| FY2020 | −$19.5M | — |
| FY2019 | −$28.5M | — |
| FY2018 | −$19.6M | — |
| FY2017 | −$7.1M | — |
| FY2016 | −$7.6M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $3.1M | — |
| Jun 2026 | −$4.0K | — |
| Mar 2026 | −$639.0K | — |
| Dec 2025 | −$6.6M | — |
| 43 more quarters | Free account |
Against its own ten years
Low −$28.5M
High $5.4M
Ten-year median
−$15.0M
Current reading's percentile
91
EBITDA against peers
| Company | EBITDA |
|---|---|
| ITGR Integer Holdings Corporation compare | $296.5M |
| TMDX TransMedics Group, Inc. compare | $126.9M |
| NEOG Neogen Corporation compare | $116.5M |
| UFPT UFP Technologies, Inc. compare | $116.0M |
| INSP Inspire Medical Systems, Inc. compare | $33.2M |
| IRTC iRhythm Holdings, Inc. compare | $1.5M |
| AXGN AxoGen, Inc. | −$4.1M |
| ESTA Establishment Labs Holdings Inc. compare | −$8.1M |
| ALMR Alamar Biosciences, Inc. compare | −$38.4M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on AXGN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement